PharmaCyte Biotech announced a 1-for-19 reverse stock split, changing how many shares represent existing holdings. The report gives no new business results or plans, so it does not change the view of the company.
The split changes how shares are grouped, but the report gives no new details about PharmaCyte's research, sales, or cash. With no reported business result or plan, there is no clear reason to change the view of the company.
Follow PharmaCyte Biotech, Inc. (PMCB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PMCB